Cargando…
Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains
BACKGROUND: Biofilms are formed by a complex bacterial community encapsulated by a polymeric matrix, with strong adherent properties and persistent phenotype. Biofilms are considered one of the most challenging areas of modern medicine. Existing antibiotics have been developed against free-floating...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215609/ https://www.ncbi.nlm.nih.gov/pubmed/30390625 http://dx.doi.org/10.1186/s12866-018-1321-6 |
_version_ | 1783368174453915648 |
---|---|
author | Cruz, Cristina D. Shah, Shreya Tammela, Päivi |
author_facet | Cruz, Cristina D. Shah, Shreya Tammela, Päivi |
author_sort | Cruz, Cristina D. |
collection | PubMed |
description | BACKGROUND: Biofilms are formed by a complex bacterial community encapsulated by a polymeric matrix, with strong adherent properties and persistent phenotype. Biofilms are considered one of the most challenging areas of modern medicine. Existing antibiotics have been developed against free-floating bacterial cells, and thus, many treatments of biofilm-related infection fail. In this study, we compared the effects of different media on biofilm growth of clinical reference strains of Staphylococci and Enterococci, including multi-drug resistant representatives. Further, we optimized the resazurin-based assay for determining the minimal biofilm inhibitory concentration (MBIC) of standard antibiotics, and evaluated its use for the determination of minimal biofilm eradication concentration (MBEC). RESULTS: We showed that tryptic soy broth supplemented with 1% glucose was an optimal media for maximum biofilm growth of all strains tested, with an extended incubation time for Enterococci. A range of parameters were tested for the resazurin assay, including concentration, temperature and time of incubation. Using quality parameters to analyze the assay’s performance, the conditions for the resazurin assay were set as follows: 4 μg/mL and 8 μg/mL, with incubation at 25 °C for 20 min and 40 min for Staphylococci and Enterococci, respectively. CONCLUSIONS: In summary, we defined conditions for optimal biofilm growth and for standardized resazurin assay for MBIC determination against six Gram-positive clinical reference strains. We also observed that MBEC determination by the resazurin-based assay is limited due to the poor detection limit of the assay. Complementary cell counting data is needed for precise determination of MBEC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12866-018-1321-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6215609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62156092018-11-08 Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains Cruz, Cristina D. Shah, Shreya Tammela, Päivi BMC Microbiol Methodology Article BACKGROUND: Biofilms are formed by a complex bacterial community encapsulated by a polymeric matrix, with strong adherent properties and persistent phenotype. Biofilms are considered one of the most challenging areas of modern medicine. Existing antibiotics have been developed against free-floating bacterial cells, and thus, many treatments of biofilm-related infection fail. In this study, we compared the effects of different media on biofilm growth of clinical reference strains of Staphylococci and Enterococci, including multi-drug resistant representatives. Further, we optimized the resazurin-based assay for determining the minimal biofilm inhibitory concentration (MBIC) of standard antibiotics, and evaluated its use for the determination of minimal biofilm eradication concentration (MBEC). RESULTS: We showed that tryptic soy broth supplemented with 1% glucose was an optimal media for maximum biofilm growth of all strains tested, with an extended incubation time for Enterococci. A range of parameters were tested for the resazurin assay, including concentration, temperature and time of incubation. Using quality parameters to analyze the assay’s performance, the conditions for the resazurin assay were set as follows: 4 μg/mL and 8 μg/mL, with incubation at 25 °C for 20 min and 40 min for Staphylococci and Enterococci, respectively. CONCLUSIONS: In summary, we defined conditions for optimal biofilm growth and for standardized resazurin assay for MBIC determination against six Gram-positive clinical reference strains. We also observed that MBEC determination by the resazurin-based assay is limited due to the poor detection limit of the assay. Complementary cell counting data is needed for precise determination of MBEC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12866-018-1321-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-03 /pmc/articles/PMC6215609/ /pubmed/30390625 http://dx.doi.org/10.1186/s12866-018-1321-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Methodology Article Cruz, Cristina D. Shah, Shreya Tammela, Päivi Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title | Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title_full | Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title_fullStr | Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title_full_unstemmed | Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title_short | Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains |
title_sort | defining conditions for biofilm inhibition and eradication assays for gram-positive clinical reference strains |
topic | Methodology Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215609/ https://www.ncbi.nlm.nih.gov/pubmed/30390625 http://dx.doi.org/10.1186/s12866-018-1321-6 |
work_keys_str_mv | AT cruzcristinad definingconditionsforbiofilminhibitionanderadicationassaysforgrampositiveclinicalreferencestrains AT shahshreya definingconditionsforbiofilminhibitionanderadicationassaysforgrampositiveclinicalreferencestrains AT tammelapaivi definingconditionsforbiofilminhibitionanderadicationassaysforgrampositiveclinicalreferencestrains |